CardiacWire

AUGUST 9, 2024

However, cardiovascular AI actually made up a larger 18% share of total H1 2024 clearances (19 devices) if you also count cardiovascular imaging AI products that the FDA technically categorized within its “Radiology” segment (e.g.

Innovation 52

Innovation TAVR Cardiovascular Imaging Plaque 52

DAIC

JANUARY 17, 2024

Christian Tesche (Division of Cardiovascular Imaging, Department of Radiology and Radiological Science, Medical University of South Carolina and Department of Cardiology, Munich University Clinic, Ludwig-Maximilian-University).

Technology 111

Technology Coronary Artery Disease Cardiovascular Disease Cardiovascular Imaging 111

CardiacWire

MAY 18, 2024

Cardiovascular AI maintains a (distant) second largest share of FDA-cleared AI products, with 10% of total clearances (90), well below radiology’s 76% share (671). Cardiovascular AI actually makes up a larger 17.4% FFRCT, coronary plaque, etc). in 2020-2022, and 13.5% since the start of 2023.

Cardiovascular Imaging 69

Cardiovascular Imaging Plaque Innovation Ablation 69

DAIC

FEBRUARY 13, 2024

25, 2024 in the European Heart Journal Cardiovascular Imaging. 25, 2024 in the European Heart Journal Cardiovascular Imaging 1. 25, 2024 in the European Heart Journal Cardiovascular Imaging 1. Presented at the European Association of Cardiovascular Imaging: Late Breaking Clinical Research and Trials.

Coronary Artery Disease 103

Coronary Artery Disease Ischemia Atherosclerosis Cardiovascular Imaging 103